GlassScriptPhysician profile
Martin Worrall
NPI 1477532497
$12,001.35
in general payments reported to CMS, 2019-2025
25 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $357 · 2021: $4,605 · 2022: $1,368 · 2023: $1,023 · 2024: $3,044 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,587 · Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,586.50 |
| Food and Beverage | $1,876.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $3,854.66 | 2021-2023 | Iluvien |
| Regeneron Pharmaceuticals, INC. | $2,711.25 | 2022-2024 | Eylea Hd |
| Alcon Vision LLC | $1,117.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $746.01 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $507.74 | 2022-2023 | Artevo 800, Callisto Eye |
| Glaukos Corporation | $312.22 | 2020-2024 | Idose |
| Bausch & Lomb Americas INC. | $279.49 | 2022-2023 | Xipere, Visudyne |
| Regeneron Healthcare Solutions, INC. | $256.84 | 2021-2024 | Eylea |
| Genentech, INC. | $232.07 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $225.78 | 2025 | Yutiq, Iluvien |
| Horizon Therapeutics Plc | $219.30 | 2022-2023 | Tepezza |
| Genentech USA, INC. | $156.04 | 2021-2025 | Vabysmo |
| Dompe US, INC. | $152.78 | 2022-2024 | Oxervate |
| Apellis Pharmaceuticals, INC. | $152.56 | 2025 | Syfovre |
| Allergan, INC. | $142.90 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $133.38 | 2022-2023 | |
| Omeros Corporation | $124.99 | 2019 | |
| Abbvie INC. | $124.99 | 2022 | |
| Coherus Oncology, INC. | $118.78 | 2023 | |
| Aerie Pharmaceuticals, INC. | $117.75 | 2019 | |
| Oyster Point Pharma, INC. | $100.66 | 2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $88.07 | 2021 | |
| Eyepoint US, INC. | $78.39 | 2021 | |
| Astellas Pharma US INC | $34.32 | 2024 | Izervay |
| Dutch Ophthalmic, USA | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Worrall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.